Entity
  • Myllia Biotechnology

    Created in 2018
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    5,562
  • Activities

  • Technologies

  • Entity types

  • Location

    Am Kanal 27, 1110 Wien, Austria

    Wien

    Austria

  • Employees

    Scale: 11-50

    Estimated: 24

  • Engaged corporates

    0
    0 0
  • Added in Motherbase

    2 months ago
Description
  • Value proposition

    Single-cell CRISPR screening - a powerful approach to fast-forward target identification and drug discovery

    Myllia Biotechnology combines CRISPR screening with single-cell RNA sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes. We utilize the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next-generation CRISPR screens.

    Our powerful approach has broad applications in identifying novel drug targets or elucidating unknown mechanisms of actions (MoA) of drugs. Each screening project is customized to the specific needs of our clients and we perturb cells with CRISPR KO, CRISPR interference or CRISPR activation coupled to high-content read-outs such as fitness, FACS and single-cell transcriptomics. Notably, we offer single-cell CRISPR screens (CROP-Seq) in cancer cells and primary immune cells, including primary human T cells to support biotech and pharma companies striving to develop novel CAR-T and TCR-T cell therapeutics.

    Functional Genomics, Pooled CRISPR Screening, Early R&D, Target Identification, Drug Discovery, T Cell Biology, Immunology, Oncology, Transcriptomics, Single-Cell RNA Sequencing, Flow Cytometry, Genomics Service Provider, Assay Development, Project Management, Customized CRISPR gRNA Design, Targeted Sequencing, Bioinformatics, CRISPR KO Screens, and CRISPR Interference Screens

  • CRISPR Screens to Fast-Forward Drug Discovery - Myllia

    Discover the most promising targets for your drug discovery campaign - Myllia's functional genomics and CRISPR screening platform.

  • https://myllia.com/
Corporate interactions BETA
Corporate TypeTweets Articles
No interactions
Similar entities
Loading...
Loading...
Social network dynamics